Navigation Links
FDA Approves Head Lice Treatment for Children and Adults

SILVER SPRING, Md., Jan. 18, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Natroba (spinosad) Topical Suspension 0.9% for the treatment of head lice infestation in patients ages 4 years and older.  


Head lice are parasitic insects found on people's head, eyebrows, and eyelashes. They feed on human blood several times a day but are not known to cause disease. Head lice are spread mainly by direct head-to-head contact with a person who already has head lice.  Lice move by crawling and can easily travel from child to child because children play closely together and often in large groups.

"Natroba provides another option for the topical treatment of head lice infestations, which are especially prevalent in the pediatric population," said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research. "Head lice is a common problem among school children in the United States."

Natroba is a topical drug product and should be applied only to the child's scalp or hair.  The product should be used exactly as prescribed by a health care professional.

The safety and effectiveness of Natroba Topical Suspension 0.9 %, has been established in two multicenter, randomized, active-controlled studies. A total of 552 subjects received a 10-minute treatment with Natroba. If live lice were seen a week later, a second treatment was applied. The proportion of subjects who were lice-free fourteen days after the final treatment of Natroba was approximately 86 percent compared to 44 percent of the control group.  

Common adverse events reported include redness or irritation of the eyes and skin.

Safety in pediatric patients below the age of 4 years has not been established. Although Natroba is not approved for use in children younger than 4 years, it is especially important not to use in infants because the product contains benzyl alcohol.   Benzyl alcohol has been associated with serious adverse reactions, including death, when applied topically to the skin of children younger than 6 months.  

Natroba is manufactured for ParaPRO LLC of Carmel, Ind.

For more information:

Approved Drugs: Questions and Answers

Media Inquiries: Shelly Burgess, 301-796-4651,

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
2. VIDEO from Endo Pharmaceuticals Available on FDA Approves New Treatment for Low Testosterone
3. FDA Approves New Dosage Strength for INTELENCE®
4. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels
5. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
6. FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment
7. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
8. FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury
9. FDA Approves New Treatment Option for Late-Stage Breast Cancer
10. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
11. FDA Approves Cymbalta® for the Management of Chronic Musculoskeletal Pain
Post Your Comments:
(Date:10/13/2015)... Science Automation (DSA), a system integration and automation engineering firm, ... the United Kingdom (UK) as the ... . The decision to open the new office comes in ... in the medical device industry throughout the UK. ... had tremendous success over the last several years in product ...
(Date:10/13/2015)... 13, 2015  Synapse Biomedical Inc. ( ) ... (PAS) studying the use of the NeuRx ® ... enroll patients. the United States ... market-approved criteria. The PAS study group met their initial ... study has since expanded the enrollment target to 150 ...
(Date:10/13/2015)... , Oct. 13 2015 ... the "US & European markets for Meniscal ... their offering. --> ) has ... European markets for Meniscal Repair - 16 Countries ... Research and Markets ( ) has ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... anesthesia and pain management services, today announced its partnership with WPC Healthcare ... data from disparate systems and organizes the data into an aggregated data repository ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec ... their sponsorship of the Microsoft Dynamics AXUG, GPUG and NAVUG Summits to take ... and NAVUG Summit are independent user conferences designed and led by users to ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology company ... a significant contract that will provide its award-winning private messaging solution to Independence ... growing success of its Relay program, IBX Wire™, which now has over 550,000 ...
(Date:10/13/2015)... ... 13, 2015 , ... A child without a healthy mouth is much more ... remote invisible aligner system, has joined with Global Dental Relief (GDR) to ... aligner treatment plan purchased, SmileCareClub will donate one clinic visit to a child in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Nordic ... unique health needs of new moms. Postnatal Omega-3, which has been named ... utilizes Nordic Naturals’ exclusive, new, ultra-concentrated omega-3 oil. This breakthrough oil combines ...
Breaking Medicine News(10 mins):